Synthetic opioids are pain-relieving drugs made entirely in a laboratory rather than derived from the opium poppy plant. They work on the same brain receptors as natural opioids like morphine, but their chemical structures are built from scratch, which allows them to be engineered for specific potency, speed, and duration. Fentanyl, the most widely known synthetic opioid, is 50 to 100 times more potent than morphine. That extreme potency is central to both their medical value and the overdose crisis: in 2024, synthetic opioids were involved in roughly 47,700 overdose deaths in the United States.
How They Differ From Natural Opioids
Opioids fall into three categories based on how they’re made. Natural opioids, including morphine and codeine, are extracted directly from the opium poppy. Semi-synthetic opioids start with one of those plant compounds and then get chemically modified in a lab. Heroin, oxycodone, and buprenorphine all fall into this group. Synthetic opioids share none of the poppy’s original molecular scaffolding. They are designed entirely through chemistry, which gives manufacturers precise control over how fast the drug takes effect, how long it lasts, and how strongly it binds to receptors.
Synthetic opioids can be grouped into four main chemical families: morphinan derivatives (like levorphanol), diphenylheptane derivatives (like methadone), benzomorphan derivatives (like pentazocine), and phenylpiperidine derivatives, the family that includes fentanyl and its many analogs. These structural differences matter because they determine how each drug behaves in the body, even though all of them ultimately target the same receptor system.
How They Work in the Brain
All opioids, whether natural or synthetic, produce their effects by binding to mu-opioid receptors, which are proteins found on nerve cells throughout the brain, spinal cord, and gut. When an opioid molecule locks into one of these receptors, it triggers a cascade of signals that dampen pain, slow breathing, and release a wave of dopamine that produces feelings of pleasure or calm.
What makes synthetic opioids different is how tightly and efficiently they bind. Fentanyl, for example, not only forms the same initial connection to the receptor that morphine does, but it can also shift deeper into the receptor’s binding pocket and lock into a second anchor point. This dual grip helps explain why fentanyl produces such a powerful response at tiny doses. Just 0.1 milligrams of intravenous fentanyl delivers the same pain relief as 10 milligrams of intravenous morphine.
Common Synthetic Opioids
Several synthetic opioids are approved for medical use. Fentanyl is the most prescribed, available as skin patches for severe chronic pain (typically changed every 72 hours), lozenges for breakthrough cancer pain, and intravenous formulations used during surgery. Methadone, another synthetic opioid, is used both for chronic pain and as the backbone of addiction treatment programs. Tramadol, tapentadol, and the ultra-short-acting surgical drugs alfentanil and remifentanil round out the medical list.
On the illicit side, the picture is more chaotic. Clandestinely manufactured fentanyl, often called “illicit fentanyl” or “street fentanyl,” is produced in unregulated labs and pressed into counterfeit pills or mixed into heroin, cocaine, and other drugs. Because there’s no quality control, the amount of fentanyl in any given pill or bag can vary wildly from dose to dose. The DEA has documented street fentanyl sold under dozens of slang names, from “China Girl” to “Murder 8.” Carfentanil, a fentanyl analog roughly 10,000 times more potent than morphine, has also appeared in the illicit supply. It was originally developed as a tranquilizer for large animals and has no approved human medical use.
Medical Uses Beyond Pain Relief
One of the more counterintuitive roles for a synthetic opioid is treating opioid addiction itself. Methadone, with its unusually long half-life of 8 to 60 hours, produces a slow, steady activation of opioid receptors that prevents withdrawal symptoms without creating the intense high of shorter-acting drugs. Patients in methadone maintenance programs take a daily oral dose, typically stabilized around 40 milligrams, which blocks the euphoric effects of heroin or other opioids if someone relapses. Long-term methadone treatment consistently outperforms short-term approaches, keeping more people in treatment and reducing mortality.
The Overdose Crisis
Synthetic opioids, primarily illicit fentanyl, have been the leading driver of drug overdose deaths in the U.S. for several years. In 2023, they were involved in 72,776 deaths. By 2024, that number dropped to 47,735, a 35.6% decline that represents the most significant reduction among any opioid category. Researchers and public health officials are still working to understand what’s behind the decline, but expanded access to naloxone, shifts in drug supply, and increased treatment capacity likely all played a role.
Even with that drop, synthetic opioids still kill more Americans than any other drug class. The core danger is their potency relative to their physical size. A lethal dose of fentanyl can be as small as two milligrams, roughly the size of a few grains of salt. People who buy pills they believe to be prescription painkillers or benzodiazepines may have no idea fentanyl is present.
Nitazenes: A Newer Class of Concern
A family of synthetic opioids called nitazenes has begun appearing in drug supplies in the U.S. and Europe. Originally developed by pharmaceutical companies in the 1950s, nitazenes were never approved as medicines. Some members of this class are far more potent than fentanyl. Isotonitazene is roughly 250 times more potent than heroin (fentanyl is about 50 times more potent), and etonitazene reaches 500 times heroin’s potency.
What makes nitazenes especially dangerous is where they’ve been found: mixed into substances sold as other opioids, benzodiazepines, and even cannabis products. This means people can be exposed to an extraordinarily potent opioid without knowing they’re taking one at all.
Why Standard Drug Tests Often Miss Them
Most workplace drug screenings use a standard five-panel urine test that checks for marijuana, cocaine, amphetamines, PCP, and a broad opioid category. That broad opioid category reliably detects natural and semi-synthetic opioids like morphine and codeine, but fentanyl has a different chemical structure and frequently slips through. Some people who use fentanyl are aware of this gap and will pass a standard employer drug test despite active use.
Specialized immunoassay tests that specifically target fentanyl do exist, and there’s been growing pressure to add fentanyl to standard testing panels. Two FDA-cleared urine tests for fentanyl are commercially available. Oral fluid testing for fentanyl, however, does not yet have an FDA-cleared option.
Reversing a Synthetic Opioid Overdose
Naloxone, the standard overdose-reversal drug, works by knocking opioids off mu-opioid receptors. It is effective against synthetic opioids, but the process can be more difficult than reversing a heroin or morphine overdose. Fentanyl’s potency and its ability to penetrate deep into the central nervous system mean that a standard dose of naloxone may not be enough. Multiple studies have documented cases requiring 8 milligrams or more to fully reverse a synthetic opioid overdose, and theoretical models suggest that even a 2-milligram intramuscular dose may be insufficient for high-exposure fentanyl cases within 10 minutes.
There’s also the problem of renarcotization. Naloxone wears off faster than fentanyl does, so a person who initially responds to naloxone can slip back into overdose once the naloxone clears their system. This is why people who receive naloxone for a suspected synthetic opioid overdose still need emergency medical attention, even if they appear to recover initially. Repeated or higher doses may be necessary to maintain the reversal long enough for the synthetic opioid to be metabolized.